Supply Stability Proven on the Production Floor

Among pharmaceutical manufacturers, it has become increasingly clear that the ability to keep factories operating without disruption, rather than research achievements, determines performance and trust. Samsung Biologics posted consolidated second-quarter revenue of 1.3209 trillion won and operating profit of 586.4 billion won this year, while Hanmi Pharmaceutical also improved supply stability by reducing the number of cases in which its own products were out of stock for more than five days by about 57% year-on-year.

This trend has emerged because, in both biopharmaceuticals and essential medicines, production disruptions can immediately lead to quality deterioration or damage to market trust. Ultimately, manufacturing competitiveness is interpreted not simply as a matter of cost, but as a core business capability encompassing order retention, client defense, and regulatory response.

Quality Control and Standardization That Determine Approval Success or Failure

Recent articles commonly show that a product’s success or failure is not determined by clinical results alone. ITM received a complete response letter (CRL), but no issues were raised regarding clinical efficacy or safety data. In Korea, a system has also been established under which companies that obtain certification for an excellent management system are deemed to have passed conformity assessment for the Good Manufacturing Practice (GMP) system for digital medical devices. In the medical products field, work is also underway to newly establish 20 national standards and revise 122 existing standards.

These changes have come about because, the more advanced the product, the more important data reliability, testing precision, and manufacturing consistency have become alongside performance itself. From revisions to the pharmacopoeia, such as changing the musk purity test item to a preservative test, to sanctions for cases involving delayed reporting of changes to clinical trial plans and violations of quality assurance standards, regulation is functioning not as a device that slows development, but as a criterion that determines qualification for market entry.

New Drug Development with Greater Weight on Clinical Strategy

For new drug developers, it now appears more important to determine what data will open the next stage than simply to increase the number of candidate substances. Domestic mRNA vaccine developers are applying for Phase 2 IND approval or entering Phase 1 trials, shifting their focus toward platform validation. Astrozen is preparing a follow-up confirmatory clinical trial and concentrating on design improvements to reduce placebo response and assessment variability, while Shaperon is increasing the possibility of technology transfer at a stage where about 20 overseas pharmaceutical companies are reviewing its pipeline materials.

This is because, in an environment where fundraising has become more difficult, the potential to connect clinical development to commercialization is being evaluated more strictly than the clinical trials themselves. As a result, companies are either increasing the predictability of pipeline operations by aiming to advance at least one new drug candidate into the Investigational New Drug (IND) application stage every year, or changing strategy to pursue both technology transfer and follow-up development simultaneously.

An Industrial Foundation Reworking Data and Collaboration Structures

At the foundation of the bio and healthcare industry, moves are also underway to redesign data and collaboration systems. A public AI training data project invested 1.6328 trillion won, yet revealed duplicate construction and quality disparities. In trauma care, efforts are being made to expand and standardize the trauma data system across all emergency medical institutions nationwide. Meanwhile, in the field of medical technology commercialization, demand for commercializing clinical ideas has grown to the point that 81.4% of 263 physician-founded startups were established after 2016.

This change reflects the reality that industrial competitiveness cannot be completed through the excellence of individual technologies alone. Going forward, how data is standardized and how hospitals, companies, and investment entities are connected in a structured way will together determine both the reproducibility of research outcomes and the speed of commercialization.